Nevro
Medical device company Nevro today announced the FDA approval and limited market release of HFX iQ with HFX AdaptivAI – a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system.
The company said HFX AdaptivAI is the only technology with artificial intelligence (AI) to provide patients suffering from chronic pain with an unprecedented level of personalized, responsive pain relief.
HFX AdaptivAI Offers:
- Relief and Beyond: HFX AdaptivAI is engineered to maximize pain relief over time by continuing to optimize therapy even when pain relief over 50% has been achieved.
- Bipole Interlacing: Proprietary technology creates customized therapy programs in real-time using direct patient input.
- Smart Power: Through therapy optimization, advanced Smart Power technology allows patients to charge their device as little as six times per year.
- Enhanced Real-Time Insights: HFX AdaptivAI technology gathers real-time quality of life (QoL) metrics and device data, enabling more impactful patient-clinician interactions. This real-time information helps patients report pain relief in significantly less time than with traditional programming.
- Advanced Proactive Remote Monitoring: With the launch of HFX AdaptivAI, physicians will have the ability to remotely monitor each of their patient's pain journey in real time through Nevro's healthcare provider portal.
